Human antimicrobial peptides in autoimmunity

References

• Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013;15(5):219.
   PubMed Web of Science ®Google Scholar
• Németh T, Mócsai A. The role of neutrophils in autoimmune diseases. Immunol Lett. 2012;143(1):9–19.
   PubMed Web of Science ®Google Scholar
• Ganguly D, Haak S, Sisirak V, et al. The role of dendritic cells in autoimmunity. Nat Rev Immunol. 2013;13(8):566–577.
   PubMed Web of Science ®Google Scholar
• Bayry J, Thirion M, Delignat S, et al. Dendritic cells and autoimmunity. Autoimmun Rev. 2004;3(3):183–187.
   PubMed Web of Science ®Google Scholar
• Vignesh P, Rawat A, Sharma M, et al. Complement in autoimmune diseases. Clin Chim Acta. 2017;465:123–130.
   PubMed Web of Science ®Google Scholar
• Maślińska M, de Luca F, Sharif K. Tuftsin-phosphorylcholine treatment of autoimmune diseases – a benefit and a message from helminths? Rheumatology. 2017;55(6):267–268.
   PubMedGoogle Scholar
• Bashi T, Shovman O, Fridkin M, et al. Novel therapeutic compound tuftsin–phosphorylcholine attenuates collagen‐induced arthritis. Clin Exp Immunol. 2016;184(1):19–28.
   PubMed Web of Science ®Google Scholar
• Zeya HI, Spitznagel JK. Antimicrobial specificity of leukocyte lysosomal cationic proteins. Science. 1966;154(3752):1049–1051.
   PubMed Web of Science ®Google Scholar
• Zeya HI, Spitznagel JK. Cationic proteins of polymorphonuclear leukocyte lysosomes. II. Composition, properties, and mechanism of antibacterial action. J Bacteriol. 1966;91(2):755–762.
   PubMed Web of Science ®Google Scholar
• Zeya HI, Spitznagel JK. Arginine-rich proteins of polymorphonuclear leukocyte lysosomes. Antimicrobial specificity and biochemical heterogeneity. J Exp Med. 1968;127(5):927–941.
   PubMed Web of Science ®Google Scholar
• Ganz T, Selsted ME, Szklarek D, et al. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985;76(4):1427–1435.
   PubMed Web of Science ®Google Scholar
• Selsted ME, Tang YQ, Morris WL, et al. Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils. J Biol Chem. 1993;268(9):6641–6648.
   PubMed Web of Science ®Google Scholar
• Harwig SS, Swiderek KM, Kokryakov VN, et al. Gallinacins: cysteine-rich antimicrobial peptides of chicken leukocytes. FEBS Lett. 1994;342(3):281–285.
   PubMed Web of Science ®Google Scholar
• Bals R, Goldman MJ, Wilson JM. Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. Infect Immun. 1998;66(3):1225–1232.
   PubMed Web of Science ®Google Scholar
• Daher KA, Lehrer RI, Ganz T, et al. Isolation and characterization of human defensin cDNA clones. Proc Natl Acad Sci USA. 1988;85(19):7327–7331.
   PubMed Web of Science ®Google Scholar
• Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem. 1992;267(32):23216–23225.
   PubMed Web of Science ®Google Scholar
• Pazgier M, Hoover DM, Yang D, et al. Human β-defensins. Cell Mol Life Sci. 2006;63(11):1294–1313.
   PubMed Web of Science ®Google Scholar
• Deptuła J, Tokarz-Deptuła B, Malinowska-Borysiak M, et al. Cathelicidins in human and animals. Postep Microbiol. 2019;58(1):19–28.
   Google Scholar
• Agerberth B, Gunne H, Odeberg J, et al. FALL-37, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995;92(1):195–199.
   PubMed Web of Science ®Google Scholar
• Larrick JW, Hirata M, Balint RF, et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63:1291–1297.
   PubMed Web of Science ®Google Scholar
• Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett. 1995;368(1):173–176.
   PubMed Web of Science ®Google Scholar
• Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408–1425.
   PubMed Web of Science ®Google Scholar
• Golec M, Reichel C, Lemieszek M, et al. Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from healthy individuals and sarcoidosis patients. J Biol Regul Homeost Agents. 2014;28(1):73–79.
   PubMed Web of Science ®Google Scholar
• Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–3959.
   PubMed Web of Science ®Google Scholar
• Kuroda K, Okumura K, Isogai H, et al. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol. 2015;5:144.
   PubMed Web of Science ®Google Scholar
• Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med. 2002;80(9):549–561.
   PubMed Web of Science ®Google Scholar
• Vandamme D, Landuyt B, Luyten W, et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280(1):22–35.
   PubMed Web of Science ®Google Scholar
• Porter EM, Dam E, Valore EV, et al. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun. 1997;65(6):2396–2401.
   PubMed Web of Science ®Google Scholar
• Schroeder BO, Ehmann D, Precht JC, et al. Paneth cell α-defensin 6 (HD-6) is an antimicrobial peptide. Mucosal Immunol. 2015;8(3):661–671.
   PubMed Web of Science ®Google Scholar
• Tripathi S, Wang G, White M, et al. Antiviral activity of the human cathelicidin, LL-37, and derived peptides on seasonal and pandemic influenza A viruses. PLoS One. 2015;10(4):e0124706.
   PubMed Web of Science ®Google Scholar
• Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986;60(3):1068–1074.
   PubMed Web of Science ®Google Scholar
• Quiñones-Mateu ME, Lederman MM, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2003;17(16):F39–F48.
   PubMed Web of Science ®Google Scholar
• Wong JH, Ng TB, Legowska A, et al. Antifungal action of human cathelicidin fragment (LL13–37) on Candida albicans. Peptides. 2011;32(10):1996–2002.
   PubMed Web of Science ®Google Scholar
• Lehrer RI, Ganz T, Szklarek D, et al. Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J Clin Invest. 1988;81(6):1829–1835.
   PubMed Web of Science ®Google Scholar
• McGwire BS, Olson CL, Tack BF, et al. Killing of African trypanosomes by antimicrobial peptides. J Infect Dis. 2003;188(1):146–152.
   PubMed Web of Science ®Google Scholar
• Wu WKK, Sung JJ, To KF, et al. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol. 2010;223(1):178–186.
   PubMed Web of Science ®Google Scholar
• Ren SX, Cheng ASL, To KF, et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res. 2012;72(24):6512–6523.
   PubMed Web of Science ®Google Scholar
• Han Q, Wang R, Sun C, et al. Human beta-defensin-1 suppresses tumor migration and invasion and is an independent predictor for survival of oral squamous cell carcinoma patients. PLoS One. 2014;9(3):e91867.
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Iwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2002;106(1):20–26.
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Hirata M, Ogawa H, et al. Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: multifunctional activities on mast cells. CDTIA. 2003;2(3):224–231.
   Google Scholar
• Yang D, Chertov O, Bykovskaia SN, et al. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286(5439):525–528.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192(7):1069–1074.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Chertov O, et al. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol. 2000;68(1):9–14.
   PubMed Web of Science ®Google Scholar
• Territo MC, Ganz T, Selsted ME, et al. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest. 1989;84(6):2017–2020.
   PubMed Web of Science ®Google Scholar
• Grigat J, Soruri A, Forssmann U, et al. Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human α-defensin family. J Immunol. 2007;179(6):3958–3965.
   PubMed Web of Science ®Google Scholar
• Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology. 2004;111(3):273–281.
   PubMed Web of Science ®Google Scholar
• Tjabringa GS, Ninaber DK, Drijfhout JW, et al. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int Arch Allergy Immunol. 2006;140(2):103–112.
   PubMed Web of Science ®Google Scholar
• Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569.
   PubMed Web of Science ®Google Scholar
• Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–1994.
   PubMed Web of Science ®Google Scholar
• Scott A, Weldon S, Buchanan PJ, et al. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One. 2011;6(10):e26525.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Murakami T, Kuwahara-Arai K, et al. Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells. Int Immunol. 2011;23(3):185–193.
   PubMed Web of Science ®Google Scholar
• Barlow PG, Li Y, Wilkinson TS, et al. The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol. 2006;80(3):509–520.
   PubMed Web of Science ®Google Scholar
• Chamorro CI, Weber G, Grönberg A, et al. The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol. 2009;129(4):937–944.
   PubMed Web of Science ®Google Scholar
• Horn M, Bertling A, Brodde MF, et al. Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid like structures and activate platelets via glycoprotein IIb/IIIa. J Thromb Haemost. 2012;10(4):647–661.
   PubMed Web of Science ®Google Scholar
• Panyutich AV, Szold O, Poon PH, et al. Identification of defensin binding to C1 complement. FEBS Lett. 1994;356(2–3):169–173.
   PubMed Web of Science ®Google Scholar
• Prohászka Z, Német K, Csermely P, et al. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmenbrane glycoprotein gq41 of HIV-1. Mol Immunol. 1997;34:809–816.
   PubMed Web of Science ®Google Scholar
• Van den Berg RH, Faber-Krol MC, van Wetering S, et al. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood. 1998;92(10):3898–3903.
   PubMed Web of Science ®Google Scholar
• Suarez-Carmona M, Hubert P, Gonzalez A, et al. ΔNp63 isoform-mediated β-defensin family up-regulation is associated with (lymph) angiogenesis and poor prognosis in patients with squamous cell carcinoma. Oncotarget. 2014;5(7):1856–1868.
   PubMedGoogle Scholar
• Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. Faseb J. 2004;18(11):1306–1308.
   PubMed Web of Science ®Google Scholar
• Oono T, Shirafuji Y, Huh W-K, et al. Effects of human neutrophil peptide-1 on the expression of interstitial collagenase and type I collagen in human dermal fibroblasts. Arch Dermatol Res. 2002;294(4):185–189.
   PubMed Web of Science ®Google Scholar
• Diana J, Simoni Y, Furio L, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med. 2013;19(1):65–73.
   PubMed Web of Science ®Google Scholar
• Vordenbäumen S, Schneider M. Defensins: potential effectors in autoimmune rheumatic disorders. Polymers. 2011;3(3):1268–1281.
   Web of Science ®Google Scholar
• Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895–4901.
   PubMed Web of Science ®Google Scholar
• Ballardini N, Johansson C, Lilja G, et al. Enhanced expression of the antimicrobial peptide LL-37 in lesional skin of adults with atopic eczema. Br J Dermatol. 2009;161(1):40–47.
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Dessein R. Defensins couple dysbiosis to primary immunodeficiency in Crohn’s disease. WJG. 2011;17(5):567–571.
   PubMed Web of Science ®Google Scholar
• Barna BP, Culver DA, Kanchwala A, et al. Alveolar macrophage cathelicidin deficiency in severe sarcoidosis. J Innate Immun. 2012;4(5–6):569–578.
   PubMed Web of Science ®Google Scholar
• Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol. 2010;6(1):40–49.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Dejou C, Pedretti N, et al. CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol. 2011;186(3):1411–1420.
   PubMed Web of Science ®Google Scholar
• Matusevicius D, Kivisäkk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5(2):101–104.
   PubMed Web of Science ®Google Scholar
• Aarvak T, Chabaud M, Miossec P, et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999;162(3):1246–1251.
   PubMed Web of Science ®Google Scholar
• Albanesi C, Scarponi C, Cavani A, et al. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81–87.
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan X-Y, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271–2279.
   PubMed Web of Science ®Google Scholar
• Atkinson MA, von Herrath M, Powers AC, et al. Current concepts on the pathogenesis of type 1 diabetes – considerations for attempts to prevent and reverse the disease. Dia Care. 2015;38(6):979–988.
   PubMed Web of Science ®Google Scholar
• Brauner H, Lüthje P, Grünler J, et al. Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q10 on inflammatory activity. Clin Exp Immunol. 2014;177(2):478–482.
   PubMed Web of Science ®Google Scholar
• Allen JS, Pang K, Skowera A, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009;58(1):138–145.
   PubMed Web of Science ®Google Scholar
• Sun J, Furio L, Mecheri R, et al. Pancreatic β-cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota. Immunity. 2015;43(2):304–317.
   PubMed Web of Science ®Google Scholar
• Németh BC, Várkonyi T, Somogyvári F, et al. Relevance of α-defensins (HNP1-3) and defensin β-1 in diabetes. World J Gastroenterol. 2014;20(27):9128–9137.
   PubMed Web of Science ®Google Scholar
• Saraheimo M, Forsblom C, Pettersson-Fernholm K, et al. Increased levels of alpha-defensin (-1, -2 and -3) in type 1 diabetic patients with nephropathy. Nephrol Dial Transplant. 2007;23(3):914–918.
   PubMed Web of Science ®Google Scholar
• Joshi MB, Lad A, Bharath Prasad AS, et al. High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation. FEBS Lett. 2013;587(14):2241–2246.
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009;30(11):513–521.
   PubMed Web of Science ®Google Scholar
• Smith JB, Haynes MK. Rheumatoid arthritis—a molecular understanding. Ann Intern Med. 2002;136(12):908–922.
   PubMed Web of Science ®Google Scholar
• Willemze A, Trouw LA, Toes RE, et al. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol. 2012;8(3):144–152.
   PubMed Web of Science ®Google Scholar
• Baillet A, Trocmé C, Berthier S, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology. 2010;49(4):671–682.
   PubMed Web of Science ®Google Scholar
• Bokarewa MI, Jin T, Tarkowski A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J Rheumatol. 2003;30(8):1719–1724.
   PubMed Web of Science ®Google Scholar
• Paulsen F, Pufe T, Conradi L, et al. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membrane. J Pathol. 2002;198(3):369–377.
   PubMed Web of Science ®Google Scholar
• Paulsen F, Pufe T, Petersen W, et al. Expression of natural peptide antibiotics in human articular cartilage and synovial membrane. Clin Diag Lab Immunol. 2001;8(5):1021–1023.
   PubMedGoogle Scholar
• Varoga D, Pufe T, Harder J, et al. Production of endogenous antibiotics in articular cartilage. Arthrit Rheum. 2004;50(11):3526–3534.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–1874.
   PubMed Web of Science ®Google Scholar
• Varoga D, Paulsen FP, Kohrs S, et al. Expression and regulation of human beta-defensin-2 in osteoarthritis cartilage. J Pathol. 2006;209(2):166–173.
   PubMed Web of Science ®Google Scholar
• Varoga D, Pufe T, Harder J, et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum. 2005;52(6):1736–1745.
   PubMedGoogle Scholar
• Varoga D, Pufe T, Mentlein R, et al. Expression and regulation of antimicrobial peptides in articular joints. Ann Anat. 2005;187(5–6):499–508.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Kaneko T, Seto M, et al. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost. 2008;14(2):186–192.
   PubMed Web of Science ®Google Scholar
• Säll J, Carlsson M, Gidlöf O, et al. The antimicrobial peptide LL-37 alters human osteoblast Ca2+ handling and induces Ca2+-independent apoptosis. J Innate Immun. 2013;5(3):290–300.
   PubMed Web of Science ®Google Scholar
• Hoffmann MH, Bruns H, Bäckdahl L, et al. The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats. Ann Rheum Dis. 2013;72(7):1239–1248.
   PubMed Web of Science ®Google Scholar
• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2(1):16039.
   PubMedGoogle Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723.
   PubMed Web of Science ®Google Scholar
• Ishii T, Onda H, Tanigawa A, et al. Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. DNA Res. 2005;12(6):429–439.
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Bezalel S, Chapnik N, et al. High alpha-defensin levels in patients with systemic lupus erythematosus. J Immunol. 2009;127(1):116–122.
   Google Scholar
• Vordenbäumen S, Fischer-Betz R, Timm D, et al. Elevated levels of human beta-defensin 2 (hBD2) and human neutrophil peptides (HNP) in systemic lupus erythematosus. Lupus. 2010;19(14):1648–1653.
   PubMed Web of Science ®Google Scholar
• Tamiya H, Tani K, Miyata J, et al. Defensin- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int. 2006;27(2):147–152.
   PubMed Web of Science ®Google Scholar
• Schultz H, Csernok E, Herlyn K, et al. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: Prevalence and clinical associations. Clin Exp Immunol. 2003;21:117–120.
   Google Scholar
• Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2 and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem. 1996;271(6):2935–2940.
   PubMed Web of Science ®Google Scholar
• Foya O, Sthoeger ZM. Defensins in systemic lupus erythematosus. Ann N Y Acad Sci. 2009;1173:365–369.
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.
   PubMed Web of Science ®Google Scholar
• Gestermann N, Di Domizio J, Lande R, et al. Netting neutrophils activate autoreactive B cells in Lupus. J Immunol. 2018;200(10):3364–3371.
   PubMed Web of Science ®Google Scholar
• Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24(2):126–135.
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151–1160.
   PubMed Web of Science ®Google Scholar
• Lande R, Chamilos G, Ganguly D, et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol. 2015;45(1):203–213.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med. 2005;202(1):135–143.
   PubMed Web of Science ®Google Scholar
• Morizane S, Yamasaki K, Mühleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol. 2012;132(1):135–143.
   PubMed Web of Science ®Google Scholar
• Hansel A, Gunther C, Ingwersen J, et al. Human slan (6-sulfo LacNAc)dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol. 2011;127:787–794.
   PubMed Web of Science ®Google Scholar
• Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5(1):5621.
   PubMedGoogle Scholar
• Frasca L, Palazzo R, Chimenti MS, et al. Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA. Front Immunol. 2018;9:1936.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Qiu J, Lin Z-T, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019;71(6):941–951.
   PubMed Web of Science ®Google Scholar
• Kiatsurayanon C, Niyonsaba F, Chieosilapatham P, et al. Angiogenic peptide (AG)-30/5C activates human keratinocytes to produce cytokines/chemokines and to migrate and proliferate via MrgX receptors. J Dermatol Sci. 2016;83(3):190–199.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Gallo RL. The critical and multifunctional roles of antimicrobial peptides in dermatology. Dermatol Clin. 2017;35(1):39–50.
   PubMed Web of Science ®Google Scholar
• Ali H. Emerging roles for MAS-related G protein-coupled receptor-X2 in host defense peptide, opioid, and neuropeptide-mediated inflammatory reactions. Adv Immunol. 2017;136:123–162.
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA. 2005;102(50):18129–18134.
   PubMed Web of Science ®Google Scholar
• Nuding S, Fellermann K, Wehkamp J, et al. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut. 2007;56(9):1240–1247.
   PubMed Web of Science ®Google Scholar
• Elphick D, Liddell S, Mahida YR. Impaired luminal processing of human defensin-5 in Crohn’s disease: persistence in a complex with chymotrypsinogen and trypsin. Am J Pathol. 2008;172(3):702–713.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA. 2010;107(19):8772–8777.
   PubMed Web of Science ®Google Scholar
• Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn’s disease of the colon. Am J Hum Genet. 2006;79(3):439–448.
   PubMed Web of Science ®Google Scholar
• Tran D-N, Wang J, Ha C, et al. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol. 2017;17(1):63.
   PubMedGoogle Scholar
• Otte J-M, Vordenbäumen S. Role of antimicrobial peptides in inflammatory bowel disease. Polymers. 2011;3(4):2010–2017.
   Web of Science ®Google Scholar
• Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31(04):463–473.
   PubMedGoogle Scholar
• Paone G, Lucantoni G, Leone A, et al. Human neutrophil peptides stimulate tumor necrosis factor-alpha release by alveolar macrophages from patients with sarcoidosis. Chest. 2009;135(2):586–587.
   PubMed Web of Science ®Google Scholar
• Nijnik A, Pistolic J, Wyatt A, et al. Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J Immunol. 2009;183(9):5788–5798.
   PubMed Web of Science ®Google Scholar
• Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280(1):41–56.
   PubMed Web of Science ®Google Scholar
• Yang D, Biragyn A, Hoover DM, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;22(1):181–315.
   PubMedGoogle Scholar
• Elssner A, Duncan M, Gavrilin M, et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1b processing and release. J Immunol. 2004;172(8):4987–4994.
   PubMed Web of Science ®Google Scholar
• Chen Q, Jin Y, Zhang K, et al. Alarmin HNP-1 promotes pyroptosis and IL-1beta release through different roles of NLRP3 inflammasome via P2X7 in LPS-primed macrophages. Innate Immun. 2014;20(3):290–300.
   PubMed Web of Science ®Google Scholar
• Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with non-immunogenic tumor antigens. J Immunol. 2001;167(11):6644–6653.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Agmon-Levin N. ASIA’ - Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.
   PubMed Web of Science ®Google Scholar
• Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:276–286.
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–491.
   PubMed Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, et al. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
   PubMed Web of Science ®Google Scholar
• Hancock REW, Haney EF, Gill EE. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol. 2016;16(5):321–334.
   PubMed Web of Science ®Google Scholar
• Groeneveld TWL, Ramwadhdoebe TH, Trouw LA, et al. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Mol Immunol. 2007;44(14):3608–3614.
   PubMed Web of Science ®Google Scholar
• Bhat S, Song Y-H, Lawyer C, et al. Modulation of the complement system by human beta-defensin 2. J Burns Wounds. 2007;5:e10.
   PubMedGoogle Scholar
• Gaboriaud C, Ling WL, Thielens NM, et al. Deciphering the fine details of C1 assembly and activation mechanisms: “mission impossible”? Front Immunol. 2014;6:565.
   Google Scholar
• Lu J, Kishore U. C1 complex: an adaptable proteolytic module for complement and non-complement functions. Front Immunol. 2017;8:592.
   PubMed Web of Science ®Google Scholar
• Lintner KE, Wu YL, Yang Y, et al. Early components of the complement classical activation pathway in human systemic autoimmune diseases. Front Immunol. 2016;7:36.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu XM, Underhill CB, et al. Tachyplesin activates the classic complement pathway to kill tumor cells. Cancer Res. 2005;65(11):4614–4622.
   PubMed Web of Science ®Google Scholar
• Berlov MN, Umnyakova ES, Leonova TS, et al. Interaction of arenicin-1 with C1q protein. Russ J Bioorg Chem. 2015;41(6):597–601.
   Google Scholar
• Ovchinnikova TV, Aleshina GM, Balandin SV, et al. Purification and primary structure of two isoforms of arenicin, a novel antimicrobial peptide from marine polychaeta Arenicola marina. FEBS Lett. 2004;577(1–2):209–214.
   PubMed Web of Science ®Google Scholar
• Umnyakova ES, Gorbunov NP, Zhakhov AV, et al. Modulation of human complement system by antimicrobial peptide arenicin-1 from Arenicola marina. Marine Drugs. 2018;16(12):480.
   Web of Science ®Google Scholar
• Ribon M, Seninet S, Mussard J, et al. Neutrophil extracellular traps exert both pro- and anti-inflammatory actions in rheumatoid arthritis that are modulated by C1q and LL-37. J Autoimmun. 2019;98:122–131.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–1535.
   PubMed Web of Science ®Google Scholar
• Leffler J, Martin M, Gullstrand B, et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol. 2012;188(7):3522–3531.
   PubMed Web of Science ®Google Scholar
• Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5(178):178ra40.
   PubMed Web of Science ®Google Scholar
• Sur Chowdhury C, Giaglis S, Walker UA, et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014;16(3):R122.
   PubMed Web of Science ®Google Scholar